Literature DB >> 9241720

The evolution and future of immunosuppression in renal transplantation.

S Goral1, J H Helderman.   

Abstract

Since the early 1960s, a number of new immunosuppressive agents have been introduced to clinical transplantation. This review will be confined to mechanism of actions, and important gains and concerns of new microemulsion formulation of cyclosporine A (Neoral), mycophenolate mofetil (MMF), FK506, brequinar sodium, sirolimus (rapamycin), leflunomide, and 15-deoxyspergualin. We will also review some of the recent studies with monoclonal antibodies.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9241720

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN： 0270-9295            Impact factor:   5.299


  3 in total

Review 1.  The tolerant recipient: looking great in someone else's genes.

Authors:  B R Rosengard; L A Turka
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 2.  Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.

Authors:  A J Olyaei; A M de Mattos; W M Bennett
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

3.  First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

Authors:  Bristi Basu; Emma Dean; Martina Puglisi; Alastair Greystoke; Michael Ong; Wendy Burke; Maria Cavallin; Graham Bigley; Christopher Womack; Elizabeth A Harrington; Stephen Green; Elisabeth Oelmann; Johann S de Bono; Malcolm Ranson; Udai Banerji
Journal:  Clin Cancer Res       Date:  2015-03-24       Impact factor: 12.531
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.